<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03966651</url>
  </required_header>
  <id_info>
    <org_study_id>15 TETE 04</org_study_id>
    <nct_id>NCT03966651</nct_id>
  </id_info>
  <brief_title>Safety Evaluation of Peptide Receptor Radionuclide Therapy (PRRT) With 177Lu-DOTA0-Tyr3-Octreotate for Refractory or Recurrent Metastatic Neuroblastoma Expressing Somatostatin Receptors</brief_title>
  <acronym>NEUROBLU 02</acronym>
  <official_title>PHASE I Clinical Study: Safety Evaluation of Peptide Receptor Radionuclide Therapy (PRRT) With 177Lu-DOTA0-Tyr3-Octreotate for Refractory or Recurrent Metastatic Neuroblastoma Expressing Somatostatin Receptors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Claudius Regaud</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut Claudius Regaud</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This multicentric, prospective study aime to determine the Maximum Tolerated Dose (MTD) of 2
      intravenous injections of 177Lu-DOTA0-Tyr3-Octreotate (177Lu-DOTATATE) administered at 6
      weeks apart in children with metastatic progressive neuroblastoma.

      The duration of study participation of each patient will be 3 months.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2020</start_date>
  <completion_date type="Anticipated">April 2022</completion_date>
  <primary_completion_date type="Anticipated">April 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Maximum Tolerated Dose (MTD) of 177Lu-DOTATATE</measure>
    <time_frame>6 weeks for each patient</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety will be evaluated using National Cancer Institute Common Terminology Criteria for Adverse Events</measure>
    <time_frame>3 months for each patient</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">22</enrollment>
  <condition>Neuroblastoma</condition>
  <arm_group>
    <arm_group_label>PRRT with 177Lu-DOTATATE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PRRT with 177Lu-DOTATATE</intervention_name>
    <description>Children will receive 2 Peptide Receptor Radionuclide Therapy (PRRT) using 177Lu-DOTATATE administered intravenously at 6 weeks interval.</description>
    <arm_group_label>PRRT with 177Lu-DOTATATE</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histologically confirmed diagnosis of neuroblastoma

          2. Must have recurrent or refractory metastatic neuroblastoma following at least two
             prior standard treatment regimen and must have no effective conventional therapy
             existing

          3. Aged between &gt; 1 to 18 years

          4. Life expectancy greater than 3 months

          5. Must have adequate organ function, bone marrow, liver and renal function

          6. Patient assent and parent(s)/legal guardian(s) written informed consent that is
             consistent with local law and ICH-GCP guidelines

        Exclusion Criteria:

          1. Chemotherapy within 4 weeks prior to the start of study treatment

          2. High dose chemotherapy with stem cell transplantation within 3 months prior biological
             therapy or investigational agents within 4 weeks prior to the start of study treatment
             or prior to passing 5 half-lives, i.e. systemic clearance, whatever comes first

          3. Radiotherapy within 30 days before starting study treatment

          4. Prior external beam radiation (EBR) therapy

               -  to more than 25% of the bone marrow

               -  to both kidneys (scatter doses of &lt; 0.5 Gy to a single kidney or radiation to
                  &lt;50% of a single kidney )
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Frédéric COURBON</last_name>
    <phone>+33 5 31 15 55 26</phone>
    <email>Courbon.frederic@iuct-oncopole.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>IUCT-O</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Frédéric COURBON</last_name>
      <phone>+33 5 31 15 55 26</phone>
      <email>Courbon.frederic@iuct-oncopole.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>May 27, 2019</study_first_submitted>
  <study_first_submitted_qc>May 27, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 29, 2019</study_first_posted>
  <last_update_submitted>May 29, 2019</last_update_submitted>
  <last_update_submitted_qc>May 29, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 31, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PRRT (Peptide Receptor Radionuclide Therapy)</keyword>
  <keyword>177Lu-DOTATATE</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuroblastoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

